文献速递淋巴瘤

阿匹莫德作为首创性PIKfyve激酶抑制剂用于治疗B细胞非霍奇金淋巴瘤的鉴定

Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma.
PubMed 文献 · Blood · 2017-01-19

通过高通量筛选临床阶段药物,鉴定出阿匹莫德(apilimod)对磷脂酰肌醇-3-磷酸5-激酶(PIKfyve)具有高度特异性,并在体外对B细胞非霍奇金淋巴瘤(B-NHL)显示选择性细胞毒活性,体内单药有效且与已批准B-NHL药物协同。生化和敲低实验及激酶结构域突变耐药发现证实其细胞毒性由PIKfyve抑制驱动,全基因组CRISPR筛选支持溶酶体功能障碍是关键因素,TFEB及CLCN7、OSTM1、SNX10等基因影响敏感性。

要点

  • 阿匹莫德是首创性PIKfyve激酶抑制剂,对B-NHL有选择性细胞毒活性。
  • 体内研究显示阿匹莫德单药有效并与已批准B-NHL药物协同。
  • PIKfyve抑制驱动细胞毒性,溶酶体功能障碍是主要因素。

核心结论

  • 阿匹莫德通过抑制PIKfyve和破坏溶酶体稳态,代表治疗B-NHL的新方法。

研究设计与样本

  • 通过高通量筛选临床阶段药物鉴定阿匹莫德,并进行体外和体内研究、生化与敲低实验、激酶结构域突变耐药发现及全基因组CRISPR筛选。

主要发现

  • 阿匹莫德对PIKfyve具有高度特异性,在体外对B-NHL显示纳摩尔级活性,与正常细胞相比具有选择性细胞毒活性。
  • 体内研究证明阿匹莫德单药有效并与已批准B-NHL药物协同。
  • 阿匹莫德介导的细胞毒性由PIKfyve抑制驱动,溶酶体功能障碍是主要因素。
  • 全基因组CRISPR筛选中,TFEB及内体/溶酶体基因CLCN7、OSTM1、SNX10被鉴定为阿匹莫德敏感性的重要决定因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We identified apilimod as an antiproliferative compound by high-throughput screening of clinical-stage drugs. Apilimod exhibits exquisite specificity for phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) lipid kinase and has selective cytotoxic activity in B-cell non-Hodgkin lymphoma (B-NHL) compared with normal cells. Apilimod displays nanomolar activity in vitro, and in vivo studies demonstrate single-agent efficacy as well as synergy with approved B-NHL drugs. Using biochemical and knockdown approaches, and discovery of a kinase domain mutation conferring resistance, we demonstrate that apilimod-mediated cytotoxicity is driven by PIKfyve inhibition. Furthermore, a critical role for lysosome dysfunction as a major factor contributing to apilimod's cytotoxicity is supported by a genome-wide CRISPR screen. In the screen, TFEB (master transcriptional regulator of lysosomal biogenesis) and endosomal/lysosomal genes CLCN7, OSTM1, and SNX10 were identified as important determinants of apilimod sensitivity. These findings thus suggest that disruption of lysosomal homeostasis with apilimod represents a novel approach to treat B-NHL.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Gayle S, Landrette S, Beeharry N, et al. Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma. Blood. 2017. PMID: 28104689. doi:10.1182/blood-2016-09-736892

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。